Please login to the form below

Not currently logged in
Email:
Password:

Ipsen appoints executive vice president

Alexandre Lebeaut also set to be chief scientific officer

Alexandre_Lebeaut_IpsenIpsen has appointed Dr Alexandre Lebeaut as its new executive VP, research and development, and chief scientific officer to focus on the firm’s strategy to address unmet medical needs.

Lebeaut joined Ipsen in 2013 as senior VP, chief development officer, global drug development and was appointed interim head of R&D in December 2016.

Prior to joining Ipsen, Lebeaut has held several leadership positions in clinical development and medical affairs with biopharmaceutical companies including Axcan Pharmaceuticals, Sanofi and Novartis.

David Meek, CEO of Ipsen, said: “Dr Lebeaut has consistently demonstrated an unwavering commitment to innovation, collaboration and successful execution of drug development strategies.

“During his four years at Ipsen, Dr Lebeaut has been instrumental in successfully leading our global development programmes.

“He will continue to lead the transformation of Ipsen’s R&D strategy to further build a differentiated and sustainable portfolio to continue to address unmet medical needs in our key areas of expertise.”

18th April 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics